IMPORTANT INVESTOR DEADLINE: Goldberg Law PC Reminds Investors With Losses in Excess of $50,000 in CorMedix, Inc. of Deadline

LOS ANGELES--(BUSINESS WIRE)-- Goldberg Law PC (www.Goldberglawpc.com) reminds investors in CorMedix, Inc. (“CorMedix” or the “Company”) (NYSE: CRMD), who purchased or otherwise acquired shares between March 12, 2011 and July 29, 2015, inclusive (the “Class Period”), of the September 4, 2015 deadline to serve as lead plaintiff in the class action.

If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

CorMedix is a biopharmaceutical company that in-licenses, develops and markets products for the treatment of cardiac, renal, and infectious diseases. According to the complaint, on June 29, 2015, SeekingAlpha.com published a report on CorMedix alleging, among other things, that: (1) CorMedix’s main product is based on a 1970s-era catheter product acquired for less than $1 million in a bankruptcy sale, apparently after at least two failed sales processes; (2) CorMedix's market size claims are greatly exaggerated; and (3) CorMedix is touting misleading clinical-data, as in-depth industry research shows its Neutrolin/Taurolidine product is a failure and “40% benefit!” versus industry standards is inaccurate. On June 29, 2015, shares of CorMedix fell over 16% as a result of the news.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, via email at [email protected], or visit our website at Goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150821005728/en/

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq. 800-977-7401
Brian Schall, Esq. 800-977-7401
[email protected]
Goldberglawpc.com
https://twitter.com/search?q=golberglawpc&src=typd
https://www.facebook.com/pages/Goldberg-Law-PC/850505465033804?fref=ts

Source: Goldberg Law PC

You May Also Be Interested In

• CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
• National pharmacare will reduce access to new medicines for 27 million privately insured Canadians
• Elijah's Xtreme Ranks #1 Fastest Growing Online Hot Sauce Brand